APP and Alzheimer disease: Similarly, Sarroca et al. [116] also recently demonstrated some neuroprotective benefits of RSV by showing that an orally fed dose of RSV (120 mg/kg/day; 16 weeks) was protective against a number of AD pathologies (increased APP content, BACE1 activity) as well as prevented impairments in cognitive behavior (open field test, novel object recognition test) in a high-fat mouse model of AD (C57BL/6, 60% kcal from fat).